NuvOx Pharma’s NVX-208 Shows Positive Results in Phase Ib/II Stroke Trial

PR Dot COM

Positive results of NuvOx Pharma’s NVX-208 in the treatment of stroke have been published at the International Stroke Conference. A randomized Phase Ib/II trial tested acute ischemic stroke patients given placebo or low, medium, or high doses of NVX-208. The primary endpoint was safety, which was demonstrated at all three dose levels. A secondary endpoint was the modified Rankin Scale (mRS), a measure of how independently patients can live in the weeks and months after the stroke. The high dose group suggested improvement in the mRS at 30 days and 90 days. See the results...

NuvOx Pharma wins AZBio Fast Lane Award

AZBio Awards Video from NuvOx Pharma on Vimeo.

NuvOx was honored with the AZBIO Fast Lane Award for the company's many achievements in the last 18 months. The award committee noted the company's advancements in clinical trials for brain cancer and stroke, the licensing agreement in hemorrhagic shock, and continued development in pre-clinical stage indications such as heart attack. A link to a press release is here: NuvOx wins AZBio Fast Lane Award

NuvOx Wins MedCity INVEST Perfect Pitch Contest

MedCity INVEST NuvOx Pharma wins 1st place out of the biopharma companies at the MedCity INVEST Perfect Pitch Contest in Chicago. At the contest, promising startup companies, offering innovative approaches or trying to solve some of the biggest problems in healthcare pitched to investors live. Participating biopharma, diagnostics, medical device, and digital health startups have been pre-selected by a panel of venture capitalists and other investors.